These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34967721)

  • 1. Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism.
    Dirienzo L; Vitulli A; Mancazzo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Blood Transfus; 2022 Nov; 20(6):505-515. PubMed ID: 34967721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
    Königsbrügge O; Weigel G; Quehenberger P; Pabinger I; Ay C
    Clin Exp Med; 2018 Aug; 18(3):325-336. PubMed ID: 29417256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dabigatran, rivaroxaban, and apixaban on fibrin network permeability, thrombin generation, and fibrinolysis.
    Taune VS; Zabczyk M; He S; Ågren A; Blombäck M; Wallén H; Skeppholm M
    Scand J Clin Lab Invest; 2024 Jul; 84(4):257-267. PubMed ID: 38953609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y; Honda Y
    J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of direct oral anticoagulants on thromboelastographic parameters and fibrin clot properties in patients with venous thromboembolism.
    Kopytek M; Zabczyk M; Natorska J; Malinowski KP; Undas A
    J Physiol Pharmacol; 2020 Feb; 71(1):. PubMed ID: 32350148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.
    Pfrepper C; Behrendt LC; Bönigk H; Siegemund T; Metze M; Franke D; Petros S; Siegemund A
    Int J Lab Hematol; 2022 Feb; 44(1):193-201. PubMed ID: 34585540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation.
    Petkovic A; Al-Khalili F; Antovic A; Ammar M; Pruner I; Vranic A; Soutari N; Zdravkovic N; Malmström RE; Jakovljevic V; Antovic JP
    Blood Coagul Fibrinolysis; 2020 Jun; 31(4):243-252. PubMed ID: 32141885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
    Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
    Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
    Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
    J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants.
    Metze M; Klöter T; Stöbe S; Rechenberger B; Siegemund R; Siegemund T; Laufs U; Petros S; Pfrepper C
    Int J Lab Hematol; 2021 Dec; 43(6):1539-1548. PubMed ID: 34097808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay.
    Artang R; Anderson M; Riley P; Nielsen JD
    Res Pract Thromb Haemost; 2017 Oct; 1(2):194-201. PubMed ID: 30046690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban/Apixaban Concentrations and Thrombin Generation Profiles in NVAF Very Elderly Patients.
    Foulon-Pinto G; Lafuente-Lafuente C; Jourdi G; Guen JL; Tall F; Puymirat E; Delrue M; Rivière L; Ketz F; Gouin-Thibault I; Mullier F; Gaussem P; Pautas E; Lecompte T; Curis E; Siguret V
    Thromb Haemost; 2023 Apr; 123(4):402-414. PubMed ID: 36395818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
    Mitrovic D; Emmens W; Naimi A; van der Mijle A; Veeger N; van Roon E; van den Bemt P
    Clin Drug Investig; 2022 Jul; 42(7):593-598. PubMed ID: 35675030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system.
    Pfrepper C; Metze M; Siegemund A; Klöter T; Siegemund T; Petros S
    Res Pract Thromb Haemost; 2020 May; 4(4):619-627. PubMed ID: 32548561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
    Ząbczyk M; Kopytek M; Natorska J; Undas A
    Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DOAC-stop can remove direct oral anticoagulants and allow analysis by global coagulation assays.
    Wang J; Lim HY; Nandurkar H; Ho P
    Int J Lab Hematol; 2023 Jun; 45(3):360-367. PubMed ID: 36691357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.
    Carter RLR; Talbot K; Hur WS; Meixner SC; Van Der Gugten JG; Holmes DT; Côté HCF; Kastrup CJ; Smith TW; Lee AYY; Pryzdial ELG
    J Thromb Haemost; 2018 Nov; 16(11):2276-2288. PubMed ID: 30176116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement and reversal of the direct oral anticoagulants.
    Samuelson BT; Cuker A
    Blood Rev; 2017 Jan; 31(1):77-84. PubMed ID: 27625113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Italian intersociety consensus on DOAC use in internal medicine.
    Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
    Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.